Is there an anti-androgen withdrawal syndrome for enzalutamide? (Q39217798)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

title

Is there an anti-androgen withdrawal syndrome for enzalutamide? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Christoph A J von Klot

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Mario W Kramer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Alena Böker

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Thomas R W Herrmann

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Inga Peters

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Markus A Kuczyk

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Jürgen E Gschwend

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Margitta Retz

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Sebastian C Schmid

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Arnulf Stenzl

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Christian Schwentner

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Tilmann Todenhöfer

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Michael Stöckle

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Carsten-Henning Ohlmann

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Ines Azone

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

René Mager

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Georg Bartsch

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Axel Haferkamp

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Axel Heidenreich

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Charlotte Piper

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

Axel S Merseburger

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

publication date

2 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

published in

World Journal of Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

1171-1176

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

Abiraterone acetate withdrawal syndrome: does it exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

Molecular biology of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

Molecular basis for the antiandrogen withdrawal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

Molecular Alterations during Progression of Prostate Cancer to Androgen Independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

The type of patients who would benefit from anti-androgen withdrawal therapy: could it be performed safely for aggressive prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

RETRACTED: Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

Novel options for the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00345-014-1288-3

Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade

21 January 2018

1 reference

12 December 2020

Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

1 reference

12 December 2020

Re: Christoph A. Von Klot, Markus A. Kuczyk, Axel S. Merseburger. No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting. Eur Urol 2014;65:258-9: Enzalutamide withdrawal syndrome: fact or ficti

1 reference

12 December 2020

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

12 December 2020

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

1 reference

12 December 2020

Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.

1 reference

12 December 2020

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

1 reference

12 December 2020

Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens

1 reference

12 December 2020

No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting

1 reference

12 December 2020

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

1 reference

12 December 2020

Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination Therapy

1 reference

12 December 2020

Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft

1 reference

12 December 2020

Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer

1 reference

12 December 2020

Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal

1 reference

12 December 2020

Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know

1 reference

12 December 2020

Withdrawal phenomenon with the antiandrogen casodex

1 reference

12 December 2020

10.1007/S00345-014-1288-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24691670 AND SRC:MED&resulttype=core&format=json

12 March 2020

1 reference